Evonik offers Tessenderlo customers secure supply of glycine

Essen, Germany-based Evonik Industries has assumed ownership of the customer list for the pharmaceutical amino acid glycine of the Tessenderlo Group of Brussels (Belgium). By the end of the year, Tessenderlo will withdraw from the glycine business completely and close its own production plant in Belgium. Evonik's product line Rexim produces the pharmaceutical amino acid based on the strict specifications of the cGMP (current Good Manufacturing Practice) at its site in Wuming (China), where it is currently expanding capacities.

With its Rexim product line, Evonik is one of the leading suppliers of pharmaceutical-grade amino acids and amino acid derivatives. Amino acids are essential ingredients in infusion solutions and pharmaceutical active ingredients for medications to treat such diseases as high blood pressure and diabetes. They are also used as dietary supplements in such products as baby food and sports nutrition.

Through intensive research in the field of white biotechnology, Evonik has continuously expanded its portfolio of pharmaceutical-grade amino acids in recent years. "Offering Tessenderlo’s customers a sustainable supply of high-quality glycine is one more step in consolidating our pharmaceutical amino acid business," says Dr. Thomas Hermann, head of the Rexim Product Line, a subsidiary of Evonik's Health & Nutrition Business Unit. Rexim’s strengths include, among others, cGMP-compliant production along the entire process chain—all the way to fine purification of the amino acids—and its global sales network. And to ensure the level of quality desired by the customer, Evonik also has the option of acquiring from Tessenderlo specially developed glycine production equipment.